Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1898

Novel Asthma Vaccine Candidate

Inventors: Dale Umetsu, Rosemarie DeKruyff, Ya-Jen Chang, Petr Illarionov

Invention Types: Therapeutics

Research Areas: Allergy/Respiratory/Pulmonary Disease, Immunology, Inflammation

Keywords: Chronic Disease, Pediatric, Vaccine

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Dr. Umetsu and his colleagues have shown that following infection of mice with influenza A virus, the incidence and severity of induced asthma is reduced. The mechanism in the lung is due to the expansion of a protective subset of natural killer T (NKT) cells, rather than of the pro-inflammatory variety. He and his colleagues have identified specific glycolipids that activate and expand the same beneficial NKT cells, including one isolated from H. pylori. Dosing the mouse by these specific glycolipids is protective.


''In the absence of influenza A or the H. pylori compound, we see an expansion of NKT cells that cause asthma and allergies,'' says Umetsu. ''We're now trying to understand how to specifically activate the inhibitory subset of NKT cells. Treatments focused on specifically expanding this inhibitory subset of cells in children might prevent the development of asthma.''

Applications:

- Preventative Asthma vaccine candidate comprised of glycolipid compounds

- Asthma therapeutic candidate comprised of glycolipid compounds

Competitive Advantages:

- Oral administration

- Preventative treatment

- Unlikely to induce adverse side effects

- Avoids need for chronic therapies to manage asthma symptoms

- Increase in patient population and patient awareness are driving up market demand

- Environment

Business Opportunity:

Exclusive License, Sponsored Project and Collaboration

Key Publications: Ya-Jen Chang, Hye Young Kim, Lee A. Albacker, Hyun Hee Lee, Nicole Baumgarth, Shizuo Akira, Paul B. Savage, Shin Endo, Takashi Yamamura, Janneke Maaskant, Naoki Kitano, Abel Singh, Apoorva Bhatt, Gurdyal S. Besra, Peter Van Den Elzen, Ben Appelmelk, Richard W. Franck, Guangwu Chen, Rosemarie H. Dekruyff, Michio Shimamura, Petr Illarionov and Dale T. Umetsu. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. Journal of Clinical Investigation, 2010 DOI: 10.1172/JCI44845

IPStatus: Pat. Pend.